NCT04803708 - Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 22, 2021

Primary Completion Date

August 7, 2022

Study Completion Date

September 5, 2022

Conditions

Diabetic Foot UlcerPseudomonas Aeruginosa InfectionStaphylococcus Aureus InfectionAcinetobacter Infection

Interventions

BIOLOGICAL

TP-102

One mL of IP solution will be applied topically per cm3 of target ulcer. The titer of each bacteriophage in TP 102 is 1x10\^9 plaque forming units per milliliter (PFU/mL).

Trial Locations (2)

91091

Hadassah Medical Center, Ein Kerem, Jerusalem

6423906

Tel Aviv Sourasky Medical Center, Tel Aviv